吉兰-巴雷综合征与COVID-19感染及疫苗接种的关联:一项基于人群的巢式病例对照研究
在以色列最大医疗机构319万余人队列中开展巢式病例对照研究,随访2021年1月1日至2022年6月30日,76例吉兰-巴雷综合征(GBS)患者匹配760例对照。多变量条件logistic回归显示,SARS-CoV-2感染与GBS风险升高相关(OR 6.30,95%CI 2.55-15.56),而接种Pfizer-BioNTech COVID-19疫苗与GBS风险降低相关(OR 0.41,95%CI 0.17-0.96)。
要点
- SARS-CoV-2感染后6周内GBS风险升高,OR为6.30(95%CI 2.55-15.56)。
- 接种Pfizer-BioNTech COVID-19疫苗后6周内GBS风险降低,OR为0.41(95%CI 0.17-0.96)。
- 暴露时间窗改为4周和8周时结果相似,但疫苗在4周时未达统计学显著。
核心结论
- 研究提示SARS-CoV-2感染与GBS风险升高相关,而接种Pfizer-BioNTech COVID-19疫苗与GBS风险降低相关。
研究设计与样本
- 在以色列最大医疗机构3193951例16岁及以上、既往无GBS诊断的患者队列中开展巢式病例对照研究,随访期为2021年1月1日至2022年6月30日。
- 每例GBS病例按年龄和性别匹配10例随机选择的对照,评估病例和对照既往6周内的SARS-CoV-2感染和COVID-19疫苗接种情况。
主要发现
- 随访期间共76例患者诊断为GBS,匹配760例对照。
- SARS-CoV-2检测阳性者:病例9例(11.8%),对照18例(2.4%)。
- 接种COVID-19疫苗者:病例8例(10.5%,均为Pfizer-BioNTech BNT162b2疫苗),对照136例(17.9%,其中134例为Pfizer-BioNTech疫苗)。
- 多变量条件logistic回归显示,SARS-CoV-2感染与GBS的OR为6.30(95%CI 2.55-15.56),COVID-19疫苗接种与GBS的OR为0.41(95%CI 0.17-0.96)。
- 暴露时间窗改为4周和8周时结果相似,但COVID-19疫苗在4周时未达统计学显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Existing data regarding occurrence of Guillain-Barré syndrome (GBS) after coronavirus disease 2019 (COVID-19) infection and vaccination are inconclusive. We aimed to assess the association between GBS and both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19 vaccine. METHODS: We conducted a nested case-control study in a cohort of 3,193,951 patients aged 16 years or older, without a diagnosis of prior GBS, from the largest health care provider in Israel. Participants were followed from January 1, 2021, until June 30, 2022, for the occurrence of GBS. Ten randomly selected controls were matched to each case of GBS on age and sex. We assessed both SARS-CoV-2 infection and COVID-19 vaccine administration in the prior 6 weeks in cases and controls. RESULTS: Overall, 76 patients were diagnosed with GBS during follow-up and were matched to 760 controls. A positive test for SARS-CoV-2 was detected in 9 (11.8%) cases and 18 (2.4%) controls. An administration of COVID-19 vaccine was detected in 8 (10.5%) cases (all Pfizer-BioNTech [BNT162b2] vaccine) and 136 (17.9%) controls (134 Pfizer-BioNTech vaccine). Multivariable conditional logistic regression models showed that the odds ratio for GBS associated with SARS-CoV-2 infection and COVID-19 vaccine administration was 6.30 (95% CI 2.55-15.56) and 0.41 (95% CI 0.17-0.96), respectively. The results were similar when exposure to SARS-CoV-2 infection or COVID-19 vaccine administration was ascertained in the prior 4 and 8 weeks, although did not reach statistical significance for COVID-19 vaccine at 4 weeks. DISCUSSION: Our study suggests that SARS-CoV-2 infection is associated with increased risk of GBS, whereas Pfizer-BioNTech COVID-19 vaccine is associated with decreased risk of GBS.
引用
- Bishara H, Arbel A, Barnett-Griness O, et al. Association Between Guillain-Barré Syndrome and COVID-19 Infection and Vaccination: A Population-Based Nested Case-Control Study. Neurology. 2023. PMID: 37852786. doi:10.1212/WNL.0000000000207900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。